Current Drug Safety

Scope & Guideline

Bridging Research and Real-World Drug Safety Solutions

Introduction

Explore the comprehensive scope of Current Drug Safety through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Current Drug Safety in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1574-8863
PublisherBENTHAM SCIENCE PUBL
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCURR DRUG SAF / Curr. Drug Saf.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 294, BUSUM 1400 AG, NETHERLANDS

Aims and Scopes

Current Drug Safety focuses on the exploration, analysis, and reporting of drug safety profiles, adverse drug reactions (ADRs), and pharmacovigilance practices. The journal aims to provide a platform for sharing knowledge and findings related to drug safety, with an emphasis on clinical implications and real-world applications.
  1. Pharmacovigilance and Drug Safety Monitoring:
    The journal emphasizes the systematic monitoring of drug effects, including the identification and reporting of adverse drug reactions, ensuring patient safety in clinical settings.
  2. Case Reports and Literature Reviews:
    Current Drug Safety publishes detailed case reports and comprehensive literature reviews that highlight unique or severe drug reactions, offering insights into clinical management and therapeutic implications.
  3. Clinical Studies and Observational Research:
    The journal supports the publication of observational studies and cohort analyses that provide valuable data on the safety and efficacy of drugs in diverse patient populations.
  4. Drug Interactions and Treatment Protocols:
    Research focusing on drug-drug interactions, treatment efficacy, and safety assessments of drug combinations is a key area of interest, reflecting the complexities of modern pharmacotherapy.
  5. Public Health and Policy Implications:
    The journal discusses the broader implications of drug safety on public health and medication policies, aiming to inform healthcare practitioners and policymakers.
Current Drug Safety has seen a rise in several emerging themes that reflect the evolving landscape of drug safety research. These trends indicate a growing awareness of complex interactions and the need for comprehensive safety assessments in various contexts.
  1. Adverse Drug Reactions Related to COVID-19 Vaccines:
    Research related to the safety profiles and adverse effects of COVID-19 vaccines has gained significant prominence, highlighting the ongoing need for vigilance in vaccination programs.
  2. Drug-Drug Interactions in Polypharmacy:
    With the increasing prevalence of polypharmacy, there is a marked rise in studies addressing drug-drug interactions, especially in vulnerable populations such as the elderly.
  3. Patient Engagement in ADR Reporting:
    Emerging studies focus on enhancing patient engagement in reporting adverse drug reactions, utilizing novel approaches to improve pharmacovigilance practices.
  4. Long-term Safety Monitoring of Biologics and Biosimilars:
    There is a growing emphasis on the long-term safety and efficacy of biologic therapies and their biosimilars, particularly in chronic conditions like autoimmune diseases.
  5. Real-World Evidence and Observational Studies:
    The trend towards utilizing real-world evidence to assess drug safety and efficacy is increasing, reflecting a shift from controlled clinical trials to observational research that captures diverse patient experiences.

Declining or Waning

In recent years, certain themes within Current Drug Safety have shown a decline in focus or frequency of publication. This shift may reflect changing priorities in drug safety research or a saturation of previously explored topics.
  1. Traditional Pharmacology Studies:
    There has been a noticeable decrease in the publication of traditional pharmacology studies that primarily focus on drug mechanisms without addressing safety or adverse effects.
  2. General Drug Efficacy Studies:
    Research solely centered on the efficacy of medications, without a clear link to safety outcomes or adverse drug reactions, has decreased, signaling a shift towards a more safety-centric approach.
  3. Herbal and Alternative Medicine Studies:
    While still relevant, the focus on the safety profiles of herbal and alternative medications appears to be waning, perhaps due to the increasing emphasis on evidence-based practices in conventional pharmacotherapy.

Similar Journals

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Championing High-Impact Research in Clinical Pharmacology
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

European Journal of Pharmacology

Advancing drug discovery through innovative research.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Journal of Pharmaceutical Health Care and Sciences

Empowering healthcare through cutting-edge pharmaceutical research.
Publisher: BMCISSN: 2055-0294Frequency: 1 issue/year

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

Expert Opinion On Drug Safety

Elevating Standards in Pharmacological Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

JOURNAL OF CLINICAL PHARMACOLOGY

Pioneering Knowledge in Medical Pharmacology
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

ANNALS OF PHARMACOTHERAPY

Connecting Research and Practice in Pharmacology
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

PHARMAZIE

Advancing pharmaceutical knowledge since 1947.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE

Innovating approaches to medical safety.
Publisher: IOS PRESSISSN: 0924-6479Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, published by IOS Press, serves as an essential platform for advancing the understanding of risk and safety within the medical domain. With an ISSN of 0924-6479 and E-ISSN of 1878-6847, this journal has been dedicated to fostering critical discourse since its inception in 1990, reflecting a continuous commitment to the field through 2024. Positioned within the Q4 category in Health Policy and Q3 in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health, the journal provides valuable insights, empirical research, and theoretical analyses that speak to the diverse challenges faced in medical safety and risk management. Although it operates under a subscription model, the journal remains a vital resource for researchers, healthcare professionals, and students alike, facilitating the exchange of innovative ideas and best practices in health risk assessment. With Scopus ranks indicating its role as a key contributor in its categories, the INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE continues to shape the landscape of medical safety and policy discussions around the globe.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

CLINICAL THERAPEUTICS

Elevating patient care with cutting-edge pharmacological insights.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.